A Systematic Review and Meta-Analysis of Clinical Outcomes of Intravitreal Anti-VEGF Agent Treatment Immediately after Cataract Surgery for Patients with Diabetic Retinopathy

Table 5

Postoperative events and treatment in the meta-analysis.

Events	No. of studies	Crude rate, n/N		Rate difference % (95% CI)	for overall effect	I^2 for heterogeneity (%)	for heterogeneity
		Intervention	Control
DR progression	3 [1, 2, 5]	12/93	34/93	0.26 [0.13, 0.54]	0.0003	27	0.26
Maculopathy progression	3 [1, 5, 6, 12]	18/128	68/127	0.10 [0.05, 0.20]	<0.00001	0	0.81
NVG progression	2 [1, 5]	1/62	7/63	0.19 [0.03, 1.13]	0.07	0	0.97
Laser photocoagulation	4 [1, 2, 5, 6]	36/132	34/130	1.13 [0.59, 2.13]	0.72	0	0.86
VH	1 [6]	1/39	1/37	0.95 [0.06, 15.72]	0.97	—	—
Elevated IOP	2 [7, 9]	3/87	0/86	4.12 [0.45, 37.82]	0.21	0	0.83
CH	1 [7]	2/23	0/23	5.47 [0.25, 120.37]	0.28	—	—

IVB = intravitreal bevacizumab; DR = diabetic retinopathy; NVG = neovascular glaucoma; CI = confidence interval; VH = vitreous hemorrhage; CH = conjunctival hemorrhage.